vs

Side-by-side financial comparison of JANUS HENDERSON GROUP PLC (JHG) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

JANUS HENDERSON GROUP PLC is the larger business by last-quarter revenue ($1.1B vs $622.0M, roughly 1.8× Royalty Pharma plc). JANUS HENDERSON GROUP PLC runs the higher net margin — 35.3% vs 34.4%, a 0.9% gap on every dollar of revenue. On growth, JANUS HENDERSON GROUP PLC posted the faster year-over-year revenue change (61.3% vs 4.8%). Over the past eight quarters, JANUS HENDERSON GROUP PLC's revenue compounded faster (43.9% CAGR vs 4.6%).

Janus Henderson is a British-American global asset management group headquartered in the City of London, United Kingdom. It offers a range of financial products to individuals, intermediary advisors, and institutional investors globally under the trade name Janus Henderson Investors.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

JHG vs RPRX — Head-to-Head

Bigger by revenue
JHG
JHG
1.8× larger
JHG
$1.1B
$622.0M
RPRX
Growing faster (revenue YoY)
JHG
JHG
+56.5% gap
JHG
61.3%
4.8%
RPRX
Higher net margin
JHG
JHG
0.9% more per $
JHG
35.3%
34.4%
RPRX
Faster 2-yr revenue CAGR
JHG
JHG
Annualised
JHG
43.9%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
JHG
JHG
RPRX
RPRX
Revenue
$1.1B
$622.0M
Net Profit
$403.2M
$214.2M
Gross Margin
Operating Margin
42.7%
62.4%
Net Margin
35.3%
34.4%
Revenue YoY
61.3%
4.8%
Net Profit YoY
231.0%
2.9%
EPS (diluted)
$2.59
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JHG
JHG
RPRX
RPRX
Q4 25
$1.1B
$622.0M
Q3 25
$700.4M
$609.3M
Q2 25
$633.2M
$578.7M
Q1 25
$621.4M
$568.2M
Q4 24
$708.3M
$593.6M
Q3 24
$624.8M
$564.7M
Q2 24
$588.4M
$537.3M
Q1 24
$551.7M
$568.0M
Net Profit
JHG
JHG
RPRX
RPRX
Q4 25
$403.2M
$214.2M
Q3 25
$142.1M
$288.2M
Q2 25
$149.9M
$30.2M
Q1 25
$120.7M
$238.3M
Q4 24
$121.8M
$208.2M
Q3 24
$27.3M
$544.0M
Q2 24
$129.7M
$102.0M
Q1 24
$130.1M
$4.8M
Operating Margin
JHG
JHG
RPRX
RPRX
Q4 25
42.7%
62.4%
Q3 25
24.6%
70.1%
Q2 25
25.9%
36.3%
Q1 25
24.7%
94.0%
Q4 24
27.9%
60.9%
Q3 24
26.4%
Q2 24
27.9%
50.2%
Q1 24
21.6%
-13.0%
Net Margin
JHG
JHG
RPRX
RPRX
Q4 25
35.3%
34.4%
Q3 25
20.3%
47.3%
Q2 25
23.7%
5.2%
Q1 25
19.4%
41.9%
Q4 24
17.2%
35.1%
Q3 24
4.4%
96.3%
Q2 24
22.0%
19.0%
Q1 24
23.6%
0.8%
EPS (diluted)
JHG
JHG
RPRX
RPRX
Q4 25
$2.59
$0.49
Q3 25
$0.92
$0.67
Q2 25
$0.95
$0.07
Q1 25
$0.77
$0.55
Q4 24
$0.77
$0.46
Q3 24
$0.17
$1.21
Q2 24
$0.81
$0.23
Q1 24
$0.81
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JHG
JHG
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$1.6B
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$5.1B
$9.7B
Total Assets
$8.3B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JHG
JHG
RPRX
RPRX
Q4 25
$1.6B
$618.7M
Q3 25
$1.4B
$938.9M
Q2 25
$1.3B
$631.9M
Q1 25
$1.4B
$1.1B
Q4 24
$1.6B
$929.0M
Q3 24
$1.8B
$950.1M
Q2 24
$1.3B
$1.8B
Q1 24
$1.1B
$843.0M
Total Debt
JHG
JHG
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
JHG
JHG
RPRX
RPRX
Q4 25
$5.1B
$9.7B
Q3 25
$4.8B
$9.6B
Q2 25
$4.8B
$9.5B
Q1 25
$4.7B
$9.8B
Q4 24
$4.6B
$10.3B
Q3 24
$4.6B
$10.3B
Q2 24
$4.5B
$9.8B
Q1 24
$4.4B
$9.9B
Total Assets
JHG
JHG
RPRX
RPRX
Q4 25
$8.3B
$19.6B
Q3 25
$7.6B
$19.3B
Q2 25
$7.5B
$18.3B
Q1 25
$7.1B
$17.6B
Q4 24
$7.0B
$18.2B
Q3 24
$7.3B
$18.0B
Q2 24
$6.4B
$17.7B
Q1 24
$6.3B
$16.1B
Debt / Equity
JHG
JHG
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JHG
JHG
RPRX
RPRX
Operating Cash FlowLast quarter
$322.7M
$827.1M
Free Cash FlowOCF − Capex
$320.4M
FCF MarginFCF / Revenue
28.0%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
0.80×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$710.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JHG
JHG
RPRX
RPRX
Q4 25
$322.7M
$827.1M
Q3 25
$258.8M
$702.6M
Q2 25
$135.2M
$364.0M
Q1 25
$2.8M
$596.1M
Q4 24
$247.3M
$742.5M
Q3 24
$228.5M
$703.6M
Q2 24
$223.8M
$658.2M
Q1 24
$-5.0M
$664.6M
Free Cash Flow
JHG
JHG
RPRX
RPRX
Q4 25
$320.4M
Q3 25
$256.4M
Q2 25
$133.2M
Q1 25
$900.0K
Q4 24
$243.5M
Q3 24
$225.9M
Q2 24
$221.9M
Q1 24
$-6.8M
FCF Margin
JHG
JHG
RPRX
RPRX
Q4 25
28.0%
Q3 25
36.6%
Q2 25
21.0%
Q1 25
0.1%
Q4 24
34.4%
Q3 24
36.2%
Q2 24
37.7%
Q1 24
-1.2%
Capex Intensity
JHG
JHG
RPRX
RPRX
Q4 25
0.2%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.3%
Q4 24
0.5%
Q3 24
0.4%
Q2 24
0.3%
Q1 24
0.3%
Cash Conversion
JHG
JHG
RPRX
RPRX
Q4 25
0.80×
3.86×
Q3 25
1.82×
2.44×
Q2 25
0.90×
12.06×
Q1 25
0.02×
2.50×
Q4 24
2.03×
3.57×
Q3 24
8.37×
1.29×
Q2 24
1.73×
6.45×
Q1 24
-0.04×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JHG
JHG

Investment Advice$585.2M51%
Investment Performance$425.8M37%
Other$76.4M7%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons